Cyfuse Biomedical K.K.
Tokyo Stock ExchangeTotal Valuation
Cyfuse Biomedical K.K. carries a market capitalization of 4.50B, placing it among publicly traded companies globally. Its enterprise value stands at 3.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.50B |
| Enterprise Value | 3.26B |
Share Statistics
Cyfuse Biomedical K.K. currently has 8.13M shares outstanding.
| Shares Outstanding | 8.13M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 95.92, and the price-to-book ratio stands at -5.43.
| PE Ratio | N/A |
| PS Ratio | 95.92 |
| PB Ratio | -5.43 |
| P/TBV Ratio | 2.00 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 53.52 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 349.73 |
Financial Position
Cyfuse Biomedical K.K. maintains a current ratio of 6.11, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.43, indicating elevated leverage, while an interest coverage ratio of -84.34 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.11 |
| Quick Ratio | 5.86 |
| Debt / Equity | 27.43 |
| Debt / EBITDA | -1.03 |
| Interest Coverage | -84.34 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -16.32 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.56 |
Taxes
| Income Tax | 2.59M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Cyfuse Biomedical K.K.'s stock has declined approximately -23.05476% over the past 52 weeks. The 50-day moving average sits at 589.68, while the 200-day moving average is 608.64.
| Beta (5Y) | N/A |
| 52-Week Price Change | -23.05476% |
| 50-Day Moving Average | 589.68 |
| 200-Day Moving Average | 608.64 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cyfuse Biomedical K.K. generated 60.88M in revenue and converted that into -671.82M in net income, yielding earnings per share of -85.02. EBITDA reached -782.74M, while operating income came in at -782.74M.
| Revenue | 60.88M |
| Gross Profit | 35.49M |
| Operating Income | -782.74M |
| Pretax Income | -669.23M |
| Net Income | -671.82M |
| EBITDA | -782.74M |
| EBIT | -782.74M |
| Earnings Per Share (EPS) | -85.02 |
Balance Sheet
Cyfuse Biomedical K.K. holds 3.39B in cash and equivalents against 804.00M in total debt, resulting in a net debt position of -2.58B. Total book value stands at -1.08B, with working capital of 2.95B providing operational flexibility.
| Cash & Cash Equivalents | 3.39B |
| Total Debt | 804.00M |
| Net Debt | -2.58B |
| Equity (Book Value) | -1.08B |
| Book Value Per Share | -136.04 |
| Working Capital | 2.95B |
Margins
Cyfuse Biomedical K.K. operates with a gross margin of 58.30, reflecting its pricing power and cost economics. The operating margin of -1,285.67 and net profit margin of -1,103.48 provide insight into operational efficiency.
| Gross Margin | 58.30 |
| Operating Margin | -1,285.67 |
| Pretax Margin | -1,099.22 |
| Profit Margin | -1,103.48 |
| EBITDA Margin | -1,285.67 |
Scores
Cyfuse Biomedical K.K. posts an Altman Z-Score of 3.21, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.21 |